Why the study?
Is coronary [¹⁸F]AlF-NOTA-FAPI-04 uptake associated with MACEs and able to differentiate in-stent restenosis in symptomatic post-PCI patients?
Cohort (n=98)
No
Is coronary [¹⁸F]AlF-NOTA-FAPI-04 uptake associated with MACEs and able to differentiate in-stent restenosis in symptomatic post-PCI patients?
FAPI PET/CT identifies high-risk coronary plaques linked to MACEs and characterizes in-stent restenosis in post-PCI patients, though short-term lipid-lowering therapy does not significantly modify this fibroblast activity.
Answers are grounded in this paper and cite their sources.
May aid post-PCI risk stratification; hypothesis-generating and requires prospective validation before clinical adoption.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) conducted a cohort in Symptomatic post-PCI coronary artery disease (n=98). FAPI PET/CT ([¹⁸F]AlF-NOTA-FAPI-04) vs. Non-CVD controls and stable coronary syndrome was evaluated on Association of coronary FAPI uptake with major adverse cardiovascular events (MACEs).
Synapse has enriched 10 related papers. Consider them for comparative context: